Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

The promise of neuroprotective agents in Parkinson's disease.

Seidl SE, Potashkin JA.

Front Neurol. 2011 Nov 21;2:68. doi: 10.3389/fneur.2011.00068. eCollection 2011. Erratum in: Front Neurol. 2013;7:69.

2.

Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson's disease.

Faust K, Gehrke S, Yang Y, Yang L, Beal MF, Lu B.

BMC Neurosci. 2009 Sep 1;10:109. doi: 10.1186/1471-2202-10-109.

3.

Disease modification in Parkinson's disease.

Henchcliffe C, Severt WL.

Drugs Aging. 2011 Aug 1;28(8):605-15. doi: 10.2165/11591320-000000000-00000. Review.

PMID:
21812497
4.

New pharmacologic horizons in the treatment of Parkinson disease.

Bonuccelli U, Del Dotto P.

Neurology. 2006 Oct 10;67(7 Suppl 2):S30-8. Review.

PMID:
17030738
5.

Plant-derived neuroprotective agents in Parkinson's disease.

Fu W, Zhuang W, Zhou S, Wang X.

Am J Transl Res. 2015 Jul 15;7(7):1189-202. eCollection 2015. Review.

6.

Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough.

Löhle M, Reichmann H.

J Neurol Sci. 2010 Feb 15;289(1-2):104-14. doi: 10.1016/j.jns.2009.08.025. Epub 2009 Sep 20. Review.

PMID:
19772974
7.

Parkinson's disease: Autoimmunity and neuroinflammation.

De Virgilio A, Greco A, Fabbrini G, Inghilleri M, Rizzo MI, Gallo A, Conte M, Rosato C, Ciniglio Appiani M, de Vincentiis M.

Autoimmun Rev. 2016 Oct;15(10):1005-11. doi: 10.1016/j.autrev.2016.07.022. Epub 2016 Aug 4. Review.

PMID:
27497913
8.

Neuroprotective effects of creatine.

Beal MF.

Amino Acids. 2011 May;40(5):1305-13. doi: 10.1007/s00726-011-0851-0. Epub 2011 Mar 30. Review.

PMID:
21448659
9.

The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.

Prediger RD, Aguiar AS Jr, Moreira EL, Matheus FC, Castro AA, Walz R, De Bem AF, Latini A, Tasca CI, Farina M, Raisman-Vozari R.

Curr Pharm Des. 2011;17(5):489-507. Review.

PMID:
21375482
10.

Advances in drug development for Parkinson's disease: present status.

Harikrishna Reddy D, Misra S, Medhi B.

Pharmacology. 2014;93(5-6):260-71. doi: 10.1159/000362419. Epub 2014 Aug 1. Review.

11.

Dopaminergic Neurons Exhibit an Age-Dependent Decline in Electrophysiological Parameters in the MitoPark Mouse Model of Parkinson's Disease.

Branch SY, Chen C, Sharma R, Lechleiter JD, Li S, Beckstead MJ.

J Neurosci. 2016 Apr 6;36(14):4026-37. doi: 10.1523/JNEUROSCI.1395-15.2016.

12.

Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson's disease.

Youdim MB, Kupershmidt L, Amit T, Weinreb O.

Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1:S132-6. doi: 10.1016/S1353-8020(13)70032-4. Review.

PMID:
24262165
13.

Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole.

Albrecht S, Buerger E.

Curr Med Res Opin. 2009 Dec;25(12):2977-87. doi: 10.1185/03007990903364954. Review.

PMID:
19842998
14.

Nutraceuticals and their preventive or potential therapeutic value in Parkinson's disease.

Chao J, Leung Y, Wang M, Chang RC.

Nutr Rev. 2012 Jul;70(7):373-86. doi: 10.1111/j.1753-4887.2012.00484.x. Epub 2012 May 22. Review.

PMID:
22747840
15.

Anti-inflammatory properties rather than anti-oxidant capability is the major mechanism of neuroprotection by sodium salicylate in a chronic rotenone model of Parkinson's disease.

Thakur P, Nehru B.

Neuroscience. 2013 Feb 12;231:420-31. doi: 10.1016/j.neuroscience.2012.11.006. Epub 2012 Nov 14.

PMID:
23159314
16.

Delayed caffeine treatment prevents nigral dopamine neuron loss in a progressive rat model of Parkinson's disease.

Sonsalla PK, Wong LY, Harris SL, Richardson JR, Khobahy I, Li W, Gadad BS, German DC.

Exp Neurol. 2012 Apr;234(2):482-7. doi: 10.1016/j.expneurol.2012.01.022. Epub 2012 Jan 28.

18.

Rasagiline in treatment of Parkinson's disease.

Nayak L, Henchcliffe C.

Neuropsychiatr Dis Treat. 2008 Feb;4(1):23-32.

19.

Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition.

Youdim MB, Bar Am O, Yogev-Falach M, Weinreb O, Maruyama W, Naoi M, Amit T.

J Neurosci Res. 2005 Jan 1-15;79(1-2):172-9. Review.

PMID:
15573406
20.

Medical management of Parkinson's disease: focus on neuroprotection.

Boll MC, Alcaraz-Zubeldia M, Rios C.

Curr Neuropharmacol. 2011 Jun;9(2):350-9. doi: 10.2174/157015911795596577.

Supplemental Content

Support Center